150
Participants
Start Date
September 30, 2006
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Glutamine dipeptide with 15% Clinisol
Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
15% Clinisol
Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
Emory University, Atlanta
University Of Wisconsin Hospital, Madison
University of Colorado Health Sciences Center, Denver
The Miriam Hospital/Brown University, Providence
Vanderbilt University, Nashville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Emory University
OTHER